Global BiSpecific MAbS Market Research Report 2023

December 2023 | 85 pages | ID: GA265CF163A1EN
QYResearch

Abstracts

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global BiSpecific MAbS market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

• Johnson & Johnson
• Novartis AG
• Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Bayer AG
• Thermo Fisher Scientific
• Bristol Myers Squibb
• Abbott

Segment by Type

• Catumaxomab (Removab™)
• Blinatumomab
• Emicizumab
• Amivantamab
• Others

Segment by Application

• Hospital
• Research Institute
• Others

By Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

The BiSpecific MAbS report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies’ Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies’ Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global BiSpecific MAbS Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
  1.2.2 Catumaxomab (Removab™)
  1.2.3 Blinatumomab
  1.2.4 Emicizumab
  1.2.5 Amivantamab
  1.2.6 Others
1.3 Market by Application
  1.3.1 Global BiSpecific MAbS Market Growth by Application: 2018 VS 2022 VS 2029
  1.3.2 Hospital
  1.3.3 Research Institute
  1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global BiSpecific MAbS Market Perspective (2018-2029)
2.2 BiSpecific MAbS Growth Trends by Region
  2.2.1 Global BiSpecific MAbS Market Size by Region: 2018 VS 2022 VS 2029
  2.2.2 BiSpecific MAbS Historic Market Size by Region (2018-2023)
  2.2.3 BiSpecific MAbS Forecasted Market Size by Region (2024-2029)
2.3 BiSpecific MAbS Market Dynamics
  2.3.1 BiSpecific MAbS Industry Trends
  2.3.2 BiSpecific MAbS Market Drivers
  2.3.3 BiSpecific MAbS Market Challenges
  2.3.4 BiSpecific MAbS Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top BiSpecific MAbS Players by Revenue
  3.1.1 Global Top BiSpecific MAbS Players by Revenue (2018-2023)
  3.1.2 Global BiSpecific MAbS Revenue Market Share by Players (2018-2023)
3.2 Global BiSpecific MAbS Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by BiSpecific MAbS Revenue
3.4 Global BiSpecific MAbS Market Concentration Ratio
  3.4.1 Global BiSpecific MAbS Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by BiSpecific MAbS Revenue in 2022
3.5 BiSpecific MAbS Key Players Head office and Area Served
3.6 Key Players BiSpecific MAbS Product Solution and Service
3.7 Date of Enter into BiSpecific MAbS Market
3.8 Mergers & Acquisitions, Expansion Plans

4 BISPECIFIC MABS BREAKDOWN DATA BY TYPE

4.1 Global BiSpecific MAbS Historic Market Size by Type (2018-2023)
4.2 Global BiSpecific MAbS Forecasted Market Size by Type (2024-2029)

5 BISPECIFIC MABS BREAKDOWN DATA BY APPLICATION

5.1 Global BiSpecific MAbS Historic Market Size by Application (2018-2023)
5.2 Global BiSpecific MAbS Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America BiSpecific MAbS Market Size (2018-2029)
6.2 North America BiSpecific MAbS Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America BiSpecific MAbS Market Size by Country (2018-2023)
6.4 North America BiSpecific MAbS Market Size by Country (2024-2029)
6.5 United States
6.6 Canada

7 EUROPE

7.1 Europe BiSpecific MAbS Market Size (2018-2029)
7.2 Europe BiSpecific MAbS Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe BiSpecific MAbS Market Size by Country (2018-2023)
7.4 Europe BiSpecific MAbS Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific BiSpecific MAbS Market Size (2018-2029)
8.2 Asia-Pacific BiSpecific MAbS Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific BiSpecific MAbS Market Size by Region (2018-2023)
8.4 Asia-Pacific BiSpecific MAbS Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia

9 LATIN AMERICA

9.1 Latin America BiSpecific MAbS Market Size (2018-2029)
9.2 Latin America BiSpecific MAbS Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America BiSpecific MAbS Market Size by Country (2018-2023)
9.4 Latin America BiSpecific MAbS Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa BiSpecific MAbS Market Size (2018-2029)
10.2 Middle East & Africa BiSpecific MAbS Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa BiSpecific MAbS Market Size by Country (2018-2023)
10.4 Middle East & Africa BiSpecific MAbS Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Johnson & Johnson
  11.1.1 Johnson & Johnson Company Detail
  11.1.2 Johnson & Johnson Business Overview
  11.1.3 Johnson & Johnson BiSpecific MAbS Introduction
  11.1.4 Johnson & Johnson Revenue in BiSpecific MAbS Business (2018-2023)
  11.1.5 Johnson & Johnson Recent Development
11.2 Novartis AG
  11.2.1 Novartis AG Company Detail
  11.2.2 Novartis AG Business Overview
  11.2.3 Novartis AG BiSpecific MAbS Introduction
  11.2.4 Novartis AG Revenue in BiSpecific MAbS Business (2018-2023)
  11.2.5 Novartis AG Recent Development
11.3 Hoffmann-La Roche Ltd.
  11.3.1 Hoffmann-La Roche Ltd. Company Detail
  11.3.2 Hoffmann-La Roche Ltd. Business Overview
  11.3.3 Hoffmann-La Roche Ltd. BiSpecific MAbS Introduction
  11.3.4 Hoffmann-La Roche Ltd. Revenue in BiSpecific MAbS Business (2018-2023)
  11.3.5 Hoffmann-La Roche Ltd. Recent Development
11.4 Novo Nordisk A/S
  11.4.1 Novo Nordisk A/S Company Detail
  11.4.2 Novo Nordisk A/S Business Overview
  11.4.3 Novo Nordisk A/S BiSpecific MAbS Introduction
  11.4.4 Novo Nordisk A/S Revenue in BiSpecific MAbS Business (2018-2023)
  11.4.5 Novo Nordisk A/S Recent Development
11.5 Bayer AG
  11.5.1 Bayer AG Company Detail
  11.5.2 Bayer AG Business Overview
  11.5.3 Bayer AG BiSpecific MAbS Introduction
  11.5.4 Bayer AG Revenue in BiSpecific MAbS Business (2018-2023)
  11.5.5 Bayer AG Recent Development
11.6 Thermo Fisher Scientific
  11.6.1 Thermo Fisher Scientific Company Detail
  11.6.2 Thermo Fisher Scientific Business Overview
  11.6.3 Thermo Fisher Scientific BiSpecific MAbS Introduction
  11.6.4 Thermo Fisher Scientific Revenue in BiSpecific MAbS Business (2018-2023)
  11.6.5 Thermo Fisher Scientific Recent Development
11.7 Bristol Myers Squibb
  11.7.1 Bristol Myers Squibb Company Detail
  11.7.2 Bristol Myers Squibb Business Overview
  11.7.3 Bristol Myers Squibb BiSpecific MAbS Introduction
  11.7.4 Bristol Myers Squibb Revenue in BiSpecific MAbS Business (2018-2023)
  11.7.5 Bristol Myers Squibb Recent Development
11.8 Abbott
  11.8.1 Abbott Company Detail
  11.8.2 Abbott Business Overview
  11.8.3 Abbott BiSpecific MAbS Introduction
  11.8.4 Abbott Revenue in BiSpecific MAbS Business (2018-2023)
  11.8.5 Abbott Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS


13 APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global BiSpecific MAbS Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Catumaxomab (Removab™)
Table 3. Key Players of Blinatumomab
Table 4. Key Players of Emicizumab
Table 5. Key Players of Amivantamab
Table 6. Key Players of Others
Table 7. Global BiSpecific MAbS Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global BiSpecific MAbS Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global BiSpecific MAbS Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global BiSpecific MAbS Market Share by Region (2018-2023)
Table 11. Global BiSpecific MAbS Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global BiSpecific MAbS Market Share by Region (2024-2029)
Table 13. BiSpecific MAbS Market Trends
Table 14. BiSpecific MAbS Market Drivers
Table 15. BiSpecific MAbS Market Challenges
Table 16. BiSpecific MAbS Market Restraints
Table 17. Global BiSpecific MAbS Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global BiSpecific MAbS Market Share by Players (2018-2023)
Table 19. Global Top BiSpecific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in BiSpecific MAbS as of 2022)
Table 20. Ranking of Global Top BiSpecific MAbS Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by BiSpecific MAbS Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players BiSpecific MAbS Product Solution and Service
Table 24. Date of Enter into BiSpecific MAbS Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global BiSpecific MAbS Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global BiSpecific MAbS Revenue Market Share by Type (2018-2023)
Table 28. Global BiSpecific MAbS Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global BiSpecific MAbS Revenue Market Share by Type (2024-2029)
Table 30. Global BiSpecific MAbS Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global BiSpecific MAbS Revenue Market Share by Application (2018-2023)
Table 32. Global BiSpecific MAbS Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global BiSpecific MAbS Revenue Market Share by Application (2024-2029)
Table 34. North America BiSpecific MAbS Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America BiSpecific MAbS Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America BiSpecific MAbS Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe BiSpecific MAbS Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe BiSpecific MAbS Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe BiSpecific MAbS Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific BiSpecific MAbS Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific BiSpecific MAbS Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific BiSpecific MAbS Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America BiSpecific MAbS Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America BiSpecific MAbS Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America BiSpecific MAbS Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa BiSpecific MAbS Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa BiSpecific MAbS Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa BiSpecific MAbS Market Size by Country (2024-2029) & (US$ Million)
Table 49. Johnson & Johnson Company Detail
Table 50. Johnson & Johnson Business Overview
Table 51. Johnson & Johnson BiSpecific MAbS Product
Table 52. Johnson & Johnson Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 53. Johnson & Johnson Recent Development
Table 54. Novartis AG Company Detail
Table 55. Novartis AG Business Overview
Table 56. Novartis AG BiSpecific MAbS Product
Table 57. Novartis AG Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 58. Novartis AG Recent Development
Table 59. Hoffmann-La Roche Ltd. Company Detail
Table 60. Hoffmann-La Roche Ltd. Business Overview
Table 61. Hoffmann-La Roche Ltd. BiSpecific MAbS Product
Table 62. Hoffmann-La Roche Ltd. Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 63. Hoffmann-La Roche Ltd. Recent Development
Table 64. Novo Nordisk A/S Company Detail
Table 65. Novo Nordisk A/S Business Overview
Table 66. Novo Nordisk A/S BiSpecific MAbS Product
Table 67. Novo Nordisk A/S Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 68. Novo Nordisk A/S Recent Development
Table 69. Bayer AG Company Detail
Table 70. Bayer AG Business Overview
Table 71. Bayer AG BiSpecific MAbS Product
Table 72. Bayer AG Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 73. Bayer AG Recent Development
Table 74. Thermo Fisher Scientific Company Detail
Table 75. Thermo Fisher Scientific Business Overview
Table 76. Thermo Fisher Scientific BiSpecific MAbS Product
Table 77. Thermo Fisher Scientific Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 78. Thermo Fisher Scientific Recent Development
Table 79. Bristol Myers Squibb Company Detail
Table 80. Bristol Myers Squibb Business Overview
Table 81. Bristol Myers Squibb BiSpecific MAbS Product
Table 82. Bristol Myers Squibb Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 83. Bristol Myers Squibb Recent Development
Table 84. Abbott Company Detail
Table 85. Abbott Business Overview
Table 86. Abbott BiSpecific MAbS Product
Table 87. Abbott Revenue in BiSpecific MAbS Business (2018-2023) & (US$ Million)
Table 88. Abbott Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global BiSpecific MAbS Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global BiSpecific MAbS Market Share by Type: 2022 VS 2029
Figure 3. Catumaxomab (Removab™) Features
Figure 4. Blinatumomab Features
Figure 5. Emicizumab Features
Figure 6. Amivantamab Features
Figure 7. Others Features
Figure 8. Global BiSpecific MAbS Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global BiSpecific MAbS Market Share by Application: 2022 VS 2029
Figure 10. Hospital Case Studies
Figure 11. Research Institute Case Studies
Figure 12. Others Case Studies
Figure 13. BiSpecific MAbS Report Years Considered
Figure 14. Global BiSpecific MAbS Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global BiSpecific MAbS Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global BiSpecific MAbS Market Share by Region: 2022 VS 2029
Figure 17. Global BiSpecific MAbS Market Share by Players in 2022
Figure 18. Global Top BiSpecific MAbS Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in BiSpecific MAbS as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by BiSpecific MAbS Revenue in 2022
Figure 20. North America BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America BiSpecific MAbS Market Share by Country (2018-2029)
Figure 22. United States BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe BiSpecific MAbS Market Share by Country (2018-2029)
Figure 26. Germany BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific BiSpecific MAbS Market Share by Region (2018-2029)
Figure 34. China BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America BiSpecific MAbS Market Share by Country (2018-2029)
Figure 42. Mexico BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa BiSpecific MAbS Market Share by Country (2018-2029)
Figure 46. Turkey BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia BiSpecific MAbS Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Johnson & Johnson Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 49. Novartis AG Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 50. Hoffmann-La Roche Ltd. Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 51. Novo Nordisk A/S Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 52. Bayer AG Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 53. Thermo Fisher Scientific Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 54. Bristol Myers Squibb Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 55. Abbott Revenue Growth Rate in BiSpecific MAbS Business (2018-2023)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed